Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Erythema

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43873   clinical trials with a EudraCT protocol, of which   7293   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    511 result(s) found for: Erythema. Displaying page 1 of 26.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-023747-15 Sponsor Protocol Number: 070411 Start Date*: 2011-05-03
    Sponsor Name:University of Oslo
    Full Title: Tick borne diseases in norwegian general practice. A randomized, controlled trial for treatment of erythema migrans in norwegian general practice. A comparison of phneoxymetylpenicillin, amoxicilli...
    Medical condition: Erythema migrans (Early Lyme disease)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10015157 Erythema chronicum migrans LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2009-009463-61 Sponsor Protocol Number: MD2009.01 Start Date*: 2009-08-06
    Sponsor Name:Sanquin Plasma Products
    Full Title: Controlled trail of immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial parvovirus B19 persistence - - a prospective, double-blind, randomized, placebo-controlled...
    Medical condition: PVB19 mediated cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056419 Dilated cardiomyopathy LLT
    9.1 10034099 Parvovirus B19 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-000712-59 Sponsor Protocol Number: APHP200073 Start Date*: 2023-03-14
    Sponsor Name:Assistance Publique - Hôpitaux Paris (Direction de la Recherche Clinique et de l’Innovation)
    Full Title: Severe erythema multiforme: A randomized controlled trial comparing a short systemic corticosteroids regimen to placebo in the acute established phase
    Medical condition: Erythema multiforme (EM) in its severe form managed at the hospital
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10015218 Erythema multiforme PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000629-30 Sponsor Protocol Number: 06022013 Start Date*: 2013-04-09
    Sponsor Name:Department of surgery, Herlev Hospital
    Full Title: The sun protective effect of melatonin: a randomized, placebo-controlled, double-blinded study on healthy volunteers.
    Medical condition: Erythema after sun exposure in healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10045745 Unspecified dermatitis due to sun LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024042-30 Sponsor Protocol Number: DUR001-301 Start Date*: 2012-05-04
    Sponsor Name:Durata Therapeutics, Inc
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO COMPARE THE EFFICACY AND SAFETY OF DALBAVANCIN TO A COMPARATOR REGIMEN (VANCOMYCIN AND LINEZOLID) FOR THE TREATMENT OF ACUTE BACTERIAL SKI...
    Medical condition: acute bacterial skin and skin structure infections (abSSSI)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10004035 Bacterial infection due to staphylococcus aureus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003136-23 Sponsor Protocol Number: CRO1990 Start Date*: 2012-11-27
    Sponsor Name:Imperial College London
    Full Title: Lamotrigine And Borderline Personality Disorder: Investigating Long-Term Effectiveness
    Medical condition: Borderline Personality Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10042033 Stevens-Johnson syndrome PT
    14.1 10029205 - Nervous system disorders 10019211 Headache PT
    15.0 100000004856 10028821 Nausea with vomiting LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10040913 Skin rash LLT
    14.1 10029205 - Nervous system disorders 10024264 Lethargy PT
    14.1 10029205 - Nervous system disorders 10013649 Drowsiness LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-003544-83 Sponsor Protocol Number: 69HCL19_0375 Start Date*: 2021-03-16
    Sponsor Name:Hospices Civils de Lyon - Direction de la Recherche Clinique
    Full Title: Evaluation de l’efficacité thérapeutique du filgrastim dans les allergies sévères bulleuses aux médicaments s’exprimant sous forme de Lyell et Stevens-Johnson Etude GNET
    Medical condition: Syndrome de Stevens Johnson (SJS) Syndrome de Lyell (NET)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004858 10042030 Stevens Johnson syndrome LLT
    20.0 100000004858 10025166 Lyell syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002130-40 Sponsor Protocol Number: DUR001-302 Start Date*: 2011-11-23
    Sponsor Name:Durata Therapeutics, Inc
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO COMPARE THE EFFICACY AND SAFETY OF DALBAVANCIN TO A COMPARATOR REGIMEN (VANCOMYCIN AND LINEZOLID) FOR THE TREATMENT OF ACUTE BACTERIAL SK...
    Medical condition: acute bacterial skin and skin structure infections (abSSSI)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10004035 Bacterial infection due to staphylococcus aureus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) LT (Completed) HU (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000419-15 Sponsor Protocol Number: DUR001-303 Start Date*: 2014-07-28
    Sponsor Name:Durata Therapeutics International B.V.
    Full Title: A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin ...
    Medical condition: Acute Bacterial Skin and Skin Structure Infections
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10052891 Skin bacterial infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed) HU (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2007-004648-54 Sponsor Protocol Number: ASF-1057-302 Start Date*: 2007-12-10
    Sponsor Name:Astion Pharma A/S
    Full Title: Efficacy and safety of ASF-1057 cream 0.5% in the treatment of seborrhoeic dermatitis: A phase III randomised, multi-centre, double-blind, active comparator (ketoconazole cream 2%) and placebo cont...
    Medical condition: Seborrhoeic dermatitis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003707-40 Sponsor Protocol Number: RD.03.SPR.40031 Start Date*: 2007-01-09
    Sponsor Name:Galderma Research and Development SNC
    Full Title: Activity of twice daily per os administration of CD06713 at 8mg versus its placebo during 4 weeks treatment, in patients with erythemato-telangiectatic rosacea.
    Medical condition: Erythemato-Telangiectatic Rosacea (ETR)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039218 Rosacea LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000608-13 Sponsor Protocol Number: MK-4117-201 Start Date*: 2017-02-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A phase III multicentre, parallel-group, randomized, placebo-controlled, double-blind clinical trial to study the efficacy and safety of MK-4117 in Japanese subjects with chronic urticaria.
    Medical condition: Chronic urticaria (a skin condition caused by an allergy)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10052568 Urticaria chronic PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003239-31 Sponsor Protocol Number: HOVIR_700 Start Date*: 2014-03-14
    Sponsor Name:HOV GmbH
    Full Title: A randomised, placebo-controlled, single-centre, double-blind study to evaluate the efficacy, safety and tolerability of topically applied piroxicam gel in patients with recurrent herpes labialis
    Medical condition: Recurrent Herpes labialis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2006-005242-36 Sponsor Protocol Number: K40-3 Start Date*: 2006-12-13
    Sponsor Name:Moberg Derma AB
    Full Title: A multicenter, randomised, double-blind, placebo-controlled clinical study evaluating efficacy, safety and tolerability of topical K40 in 8 weeks treatment of adult patients with moderate to severe...
    Medical condition: Seborrhoeic Dermatitis of the scalp.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039794 Seborrhoeic dermatitis capitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003615-22 Sponsor Protocol Number: EXP-1373 Start Date*: 2019-05-28
    Sponsor Name:LEO Pharma A/S
    Full Title: Efficacy and safety of twice-daily application of delgocitinib cream 20 mg/g for 6 weeks in subjects with active discoid lupus erythematosus. A phase 2a exploratory, randomised, double-blind, vehi...
    Medical condition: Discoid lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10013072 Discoid lupus erythematosus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001175-38 Sponsor Protocol Number: 6520-9170-08 Start Date*: 2012-01-13
    Sponsor Name:MEDICE Arzneimittel Pütter GmbH & CO.KG
    Full Title: A multi-center, randomized, double-blind,phase II trial with intraindividual comparison to assess superiority of Soventol HydroCort 0.5 % Cremogel vs vehicle on lesional skin in patients with mild ...
    Medical condition: manifest atopic dermatitis diagnosed according to Hanifin and Rajka, or seborrheic eczema or stasis dermatitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005637-37 Sponsor Protocol Number: ASF-1057-206 Start Date*: 2007-02-28
    Sponsor Name:Astion Danmark A/S
    Full Title: Comparative, placebo controlled, double-blind efficacy and safety study in patients with seborrhoeic dermatitis comparing a topical cream containing 2% Nicotinamide combined with either 0%, 0.5% or...
    Medical condition: Seborrhoeic Dermatitis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002159-89 Sponsor Protocol Number: NLD-PEG-14-10784 Start Date*: 2015-11-05
    Sponsor Name:Biogen MA
    Full Title: Brimonidine Tartrate for the Treatment of Injection Related Erythema Associated with Sub-cutaneous Administration of Peginterferon beta-1a
    Medical condition: Erythema at injection site after Plegridy injection for the treatment of Multiple Sclerose.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000852-40 Sponsor Protocol Number: TBSH-01 Start Date*: 2012-08-03
    Sponsor Name:Dermal Laboratories
    Full Title: A double-blind, placebo-controlled study determining the efficacy of terbinafine shampoo in the treatment of pityriasis capitis and seborrhoeic dermatitis.
    Medical condition: The two severe dandruff conditions to be investigated in this study are pityriasis capitis and seborrhoeic dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10011859 Dandruff PT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10039794 Seborrhoeic dermatitis capitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-024033-24 Sponsor Protocol Number: 11-01/BSal-L Start Date*: 2011-05-31
    Sponsor Name:Dermapharm AG
    Full Title: Doppelblinde, randomisierte klinische Studie zum Vergleich der Wirksamkeit und Verträglichkeit von Betamethason 0,05%_Salicylsäure 2% Lösung vs. Diprosalic Lösung vs. Grundlage bei Patienten mit Ps...
    Medical condition: Psoriasis capitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10037157 Psoriasis of scalp LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 08 00:04:16 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA